

Prof. Dr. med Philip Wenzel

*28.07.1976

Center for Cardiology, Medicine
 Johannes Gutenberg-University Mainz
 Langenbeckstraße 1
 55131 Mainz
 Tel.: +49 6131 17-7695
 E-Mail: wenzelp@uni-mainz.de


Academia

- | | |
|-------------|--|
| 2010 | Habilitation, IIInd Medical Clinic, University Medical Center, Johannes-Gutenberg University Mainz (|
| 2003 | MD Thesis, Institute for Sports Medicine, University Hamburg |
| 1995 – 2002 | Medical School, Friedrich Alexander-University Erlangen-Nürnberg and University Hamburg |

Career

- | | |
|-------------|--|
| Since 2022 | Extra-ordinary Professorship, University Medical Center, Johannes Gutenberg-University Mainz |
| Since 2020 | Head of Heart Failure Unit (HFUZ037), at University Medical Medical |
| Since 2019 | Deputy Director, Center for Cardiology - Cardiology I, University Medical Center, Johannes Gutenberg-University Mainz |
| 2016 –2022 | W2 Professorship "Vascular Inflammation" at the Center for Cardiology, Cardiology I, and CTH, University Medical Center, Johannes Gutenberg-University Mainz |
| 2011 – 2014 | Junior Research Group Leader, CTH, University Medical Center, Johannes Gutenberg-University Mainz (Prof. Dr.U. Walter) |
| 2005 – 2006 | Postdoctoral Fellow in the Laboratory for Molecular Cardiology, University Medical Center, Johannes Gutenberg-University Mainz (Prof. Dr. T. Münzel) |
| 2003 – 2009 | Residency in Internal Medicine and Cardiology (Prof. Dr. T. Meinertz; Prof. Dr. C. Huber; Prof. Dr. T. Münzel); University Medical Center Hamburg Eppendorf and UMCN |

Awards

- | | |
|------|---|
| 2020 | Fellow of the European Society of Cardiology, Member of the ESC Grants and Research Committee |
| 2017 | DZHK paper of the month February 2017 and December 2022 |
| 2017 | Principal Investigator, Deutsches Zentrum für Herz-Kreislauftforschung (DZHK) |
| 2012 | Paul-Schölmerich-Preis für Innere Medizin |
| 2000 | Stipend of the German-Chinese Society for Medicine |

Patents

Description	Publication Number	Granted
Targeting Myeloid Cell Coagulation Signaling Blocks Map Kinase/TGF-β1 Fibrotic Cardiac Remodeling in Ischemic Heart Disease	WO 2022/106648 A1	in patent process

Selected Publications

Garlapati V, Molitor M, Michna T, Harms GS, Finger S, Jung R, Lagrange J, Efentakis P, Wild J, Knorr M, Karbach S, Wild S, Vujacic-Mirski K, Münzel T, Daiber A, Brandt M, Gori T, Milting H, Tenzer S, Ruf W, Wenzel P. Targeting myeloid cell coagulation signaling blocks MAP kinase/TGF- β 1 driven fibrotic remodeling in ischemic heart failure. *J Clin Invest.* 2022 Dec 22:e156436. doi: 10.1172/JCI156436. Online ahead of print. IF 19,5

Efentakis P, Molitor M, Kossman S, Bochenek ML, Wild J, Lagrange J, Finger S, Jung R, Karbach S, Schäfer K, Schulz A, Wild P, Münzel T, Wenzel P. Tubulin-folding cofactor E deficiency promotes vascular dysfunction by increased endoplasmic reticulum stress. *Eur Heart J.* (2022). 43:488-500.

Molitor M, Rudi WS, Garlapati V, Finger S, Schuler R, Kossman S, Lagrange J, Nguyen TS, Wild J, Knopp T, Karbach SH, Knorr M, Ruf W, Munzel T, Wenzel P. Nox2+ myeloid cells drive vascular inflammation and endothelial dysfunction in heart failure after myocardial infarction via angiotensin II receptor type 1. *Cardiovasc Res.* (2021). 117:162-177.

Finger S, Knorr M, Molitor M, Schuler R, Garlapati V, Waisman A, Brandt M, Munzel T, Bopp T, Kossman S, Karbach S, Wenzel P. A sequential interferon gamma directed chemotactic cellular immune response determines survival and cardiac function post-myocardial infarction. *Cardiovasc Res.* (2019). 115:1907-1917.

Kossman S*, Lagrange J*, Jackel S, Jurk K, Ehlken M, Schonfelder T, Weihert Y, Knorr M, Brandt M, Xia N, Li H, Daiber A, Oelze M, Reinhardt C, Lackner K, Gruber A, Monia B, Karbach SH, Walter U, Ruggeri ZM, Renne T, Ruf W, Münzel T, Wenzel P. Platelet-localized FXI promotes a vascular coagulation-inflammatory circuit in arterial hypertension. *Sci Transl Med.* (2017). 9: pii: eaah4923

Karbach SH, Schonfelder T, Brandao I, Wilms E, Hormann N, Jackel S, Schuler R, Finger S, Knorr M, Lagrange J, Brandt M, Waisman A, Kossman S, Schäfer K, Münzel T, Reinhardt C, Wenzel P. Gut Microbiota Promote Angiotensin II-Induced Arterial Hypertension and Vascular Dysfunction. *J Am Heart Assoc.* (2016). 5: pii: e003698

Wenzel P, Rossmann H*, Muller C*, Kossman S*, Oelze M, Schulz A, Arnold N, Simsek C, Lagrange J, Klemz R, Schonfelder T, Brandt M, Karbach SH, Knorr M, Finger S, Neukirch C, Hauser F, Beutel ME, Kroller-Schon S, Schulz E, Schnabel RB, Lackner K, Wild PS, Zeller T, Daiber A, Blankenberg S, Münzel T. Heme oxygenase-1 suppresses a pro-inflammatory phenotype in monocytes and determines endothelial function and arterial hypertension in mice and humans. *Eur Heart J.* (2015). 36:3437-3446.

Kossman S*, Schwenk M*, Hausding M*, Karbach SH, Schmidgen MI, Brandt M, Knorr M, Hu H, Kroller-Schon S, Schonfelder T, Grabbe S, Oelze M, Daiber A, Münzel T*, Becker C*, Wenzel P*. Angiotensin II-Induced Vascular Dysfunction Depends on Interferon-gamma-driven Immune Cell Recruitment and Mutual Activation of Monocytes and NK-Cells. *Arterioscler Thromb Vasc Biol.* (2013). 33:1313-1319.

Wenzel P*, Knorr M*, Kossman S, Stratmann J, Hausding M, Schuhmacher S, Karbach SH, Schwenk M, Yoge N, Schulz E, Oelze M, Grabbe S, Jonuleit H, Becker C, Daiber A, Waisman A, Münzel T. Lysozyme M-Positive Monocytes Mediate Angiotensin II-Induced Arterial Hypertension and Vascular Dysfunction. *Circulation* (2011). 124:1370-1381.

Wenzel P, Hink U, Oelze M, Schuppan S, Schaeuble K, Schildknecht S, Ho KK, Weiner H, Bachschmid M, Munzel T, Daiber A. Role of reduced lipoic acid in the redox regulation of mitochondrial aldehyde dehydrogenase (ALDH-2) activity. Implications for mitochondrial oxidative stress and nitrate tolerance. *J Biol Chem* 2007;282:792-799. IF 5,6